US OptionsDetailed Quotes
GERN240726P4000
- 0.15
- 0.000.00%
15min DelayClose Jul 2 14:32 ET
0.00High0.00Low
0.00Open0.15Pre Close0 Volume10 Open Interest4.00Strike Price0.00Turnover213.33%IV17.74%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.2143Delta0.2668Gamma31.20Leverage Ratio-0.0375Theta-0.0001Rho-6.69Eff Leverage0.0015Vega
Geron Stock Discussion
折扣价赶快买！
On June 2, 2024, Barclays initiated coverage of Geron Corporation (NasdaqGS:GERN) with an Overweight rating, setting a price target of $9. At the time of this announcement, Geron’s stock was trading at $4.83, indicating a bullish sentiment from Barclays and predicting significant potential upside for investors. $Geron(GERN.US)$
https://stockregion.app/p/investment-bank-initiates-overweight
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US)$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US)$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US)$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
This could get interesting considering the short stats.
2.85 days to cover. 10.46% short floats.
On June 7, 2024, Geron Corporation, a commercial-stage biopharmaceutical company, proudly announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), marking a milestone in the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This ...
No comment yet